• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

硫酸伪麻黄碱四种缓释制剂的体内/体外相关性

In-vivo/in-vitro correlation of four extended release formulations of pseudoephedrine sulfate.

作者信息

Mojaverian P, Rosen J, Vadino W A, Liebowitz S, Radwanski E

机构信息

Department of Drug Metabolism & Pharmacokinetics, Schering-Plough Research Institute, Kenilworth, NJ 07033, USA.

出版信息

J Pharm Biomed Anal. 1997 Jan;15(4):439-45. doi: 10.1016/s0731-7085(96)01834-1.

DOI:10.1016/s0731-7085(96)01834-1
PMID:8953486
Abstract

An in-vivo/in-vitro correlation was established for four formulations of pseudoephedrine sulfate modified release tablets exhibiting different in-vivo and in-vitro release rate and absorption characteristics. In-vitro release rate data were obtained for 12 individual tablets of each formulation using the USP Apparatus 2 paddle stirrer at 50 rev min-1 in 1000 ml 0.1 N hydrochloric acid for the first hour followed by 0.1 M phosphate buffer at pH 7.5 for hours 2-16. Inspection of the individual and mean release rate data indicated that the in-vitro release rate of pseudoephedrine sulfate was consistent with the intended design of the four extended release formulations. The in-vivo bioavailability and pharmacokinetics of these formulations were evaluated in 20 healthy volunteers under fasted conditions. Wagner-Nelson analyses of the in-vivo data revealed extended release absorption profiles for all four formulations. Linear regression analyses of the mean percentage of dose absorbed versus the mean in-vitro release resulted in statistically significant correlations (r2 > 0.99, p < 0.0001) for each formulation. Qualitative rank order correlations were observed among all combinations of in-vivo and in-vitro parameters. These data support a Level A correlation between in-vivo absorption profiles and in-vitro release rates of four pseudoephedrine sulfate extended release formulations determined in fasted healthy volunteers.

摘要

建立了四种硫酸伪麻黄碱缓释片制剂的体内/体外相关性,这些制剂呈现出不同的体内和体外释放速率及吸收特性。使用美国药典装置2桨式搅拌器,在1000 ml 0.1 N盐酸中于50转/分钟搅拌1小时,随后在pH 7.5的0.1 M磷酸盐缓冲液中搅拌2 - 16小时,获取了每种制剂12片单片片剂的体外释放速率数据。对单片片剂和平均释放速率数据的检查表明,硫酸伪麻黄碱的体外释放速率与四种缓释制剂的预期设计一致。在禁食条件下,对20名健康志愿者评估了这些制剂的体内生物利用度和药代动力学。对体内数据进行的Wagner-Nelson分析显示,所有四种制剂均呈现缓释吸收曲线。各制剂的吸收剂量平均百分比与体外平均释放量的线性回归分析得出具有统计学意义的相关性(r2 > 0.99,p < 0.0001)。在体内和体外参数的所有组合之间观察到定性等级顺序相关性。这些数据支持在禁食健康志愿者中测定的四种硫酸伪麻黄碱缓释制剂的体内吸收曲线与体外释放速率之间具有A级相关性。

相似文献

1
In-vivo/in-vitro correlation of four extended release formulations of pseudoephedrine sulfate.硫酸伪麻黄碱四种缓释制剂的体内/体外相关性
J Pharm Biomed Anal. 1997 Jan;15(4):439-45. doi: 10.1016/s0731-7085(96)01834-1.
2
Correlation of in vitro release rate and in vivo absorption characteristics of four chlorpheniramine maleate extended-release formulations.
Pharm Res. 1992 Apr;9(4):450-6. doi: 10.1023/a:1015823926152.
3
Influence of food on the oral bioavailability of loratadine and pseudoephedrine from extended-release tablets in healthy volunteers.食物对健康志愿者口服氯雷他定和伪麻黄碱缓释片后口腔生物利用度的影响。
J Clin Pharmacol. 1996 Oct;36(10):923-30. doi: 10.1002/j.1552-4604.1996.tb04759.x.
4
Extended release dosage form of glipizide: development and validation of a level A in vitro-in vivo correlation.格列吡嗪缓释剂型:A级体外-体内相关性的开发与验证
Biol Pharm Bull. 2008 Oct;31(10):1946-51. doi: 10.1248/bpb.31.1946.
5
In-vitro and in-vivo correlation for two gliclazide extended-release tablets.两种格列齐特缓释片的体外与体内相关性
J Pharm Pharmacol. 2007 Jul;59(7):971-6. doi: 10.1211/jpp.59.7.0009.
6
Pharmacokinetics of loratadine and pseudoephedrine following single and multiple doses of once- versus twice-daily combination tablet formulations in healthy adult males.健康成年男性单次及多次服用一日一次与一日两次复方片剂后氯雷他定和伪麻黄碱的药代动力学。
Clin Ther. 1997 Sep-Oct;19(5):1002-12. doi: 10.1016/s0149-2918(97)80052-5.
7
In vitro and in vivo evaluation of a once-daily controlled-release pseudoephedrine product.
J Clin Pharmacol. 1995 Mar;35(3):259-67. doi: 10.1002/j.1552-4604.1995.tb04056.x.
8
Bioavailability of pseudoephedrine from controlled release formulations in the presence of guaifenesin in human volunteers.
Biopharm Drug Dispos. 1995 Jul;16(5):381-91. doi: 10.1002/bdd.2510160503.
9
Development of near zero-order release dosage forms using three-dimensional printing (3-DP) technology.使用三维打印(3-DP)技术开发近零级释放剂型。
Drug Dev Ind Pharm. 2006 Mar;32(3):367-76. doi: 10.1080/03639040500519300.
10
Time-controlled release pseudoephedrine tablets: bioavailability and in vitro/in vivo correlations.控释伪麻黄碱片:生物利用度及体外/体内相关性
Pharmazie. 2001 Sep;56(9):718-23.

引用本文的文献

1
Underestimation of sudden deaths among patients with seizures and epilepsy.癫痫发作和癫痫患者中猝死的低估情况。
Neurology. 2017 Aug 29;89(9):886-892. doi: 10.1212/WNL.0000000000004292. Epub 2017 Aug 2.
2
Development of spray dried liposomal dry powder inhaler of Dapsone.氨苯砜喷雾干燥脂质体干粉吸入剂的研发。
AAPS PharmSciTech. 2008;9(1):47-53. doi: 10.1208/s12249-007-9024-6. Epub 2008 Jan 9.
3
Nano-liposomal dry powder inhaler of tacrolimus: preparation, characterization, and pulmonary pharmacokinetics.他克莫司纳米脂质体干粉吸入剂:制备、表征及肺部药代动力学
Int J Nanomedicine. 2007;2(4):675-88.
4
Bias in the Wagner-Nelson estimate of the fraction of drug absorbed.瓦格纳-纳尔逊法估算药物吸收分数中的偏差。
Pharm Res. 2002 Apr;19(4):470-6. doi: 10.1023/a:1015195612726.